Pharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 Trial
MT Newswires Live
Yesterday
Pharvaris (PHVS) said Thursday the phase 3 study of its experimental drug, deucrictibant, for on-demand treatment of hereditary angioedema attacks met its main and all 11 secondary goals.
The study showed that deucrictibant stopped symptoms from worsening, relieved symptoms and achieved complete symptom resolution significantly faster than placebo, the company said.
The company said the US Food and Drug Administration is reviewing its application, with a decision expected by April 23, 2027.
The European Medicines Agency is also reviewing its marketing application, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.